Off-target vascular effects of cholesteryl ester transfer protein inhibitors involve redox-sensitive and signal transducer and activator of transcription 3-dependent pathwayss

Journal of Pharmacology and Experimental Therapeutics

Volumn 357, Issue 2, 2016, Pages 415-422

  Rios, Francisco J ^a   Lopes, Rheure A ^a,b   Neves, Karla B ^a,b   Camargo, Livia L ^a   Montezano, Augusto C ^a   Touyz, Rhian M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; ACETYLCYSTEINE; ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CONTRACTILE PROTEIN; CYCLINE; DALCETRAPIB; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN LIGHT CHAIN; MYOSIN PHOSPHATASE TARGET SUBUNIT 1; OXYGEN; PHENYLEPHRINE; PROTEIN TYROSINE KINASE; TORCETRAPIB; UNCLASSIFIED DRUG; 2 (2 CHLOROPHENYL) 4 [3 (DIMETHYLAMINO)PHENYL] 5 METHYL 1H PYRAZOLO[4,3 C]PYRIDINE 3,6(2H,5H) DIONE; CHOLESTEROL ESTER TRANSFER PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 1; PPP1R12A PROTEIN, RAT; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCAVENGER; STAT3 PROTEIN; STAT3 PROTEIN, RAT; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; EC50; ENZYME PHOSPHORYLATION; EX VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; SUPERIOR MESENTERIC ARTERY; VASCULAR SMOOTH MUSCLE CELL; VASOCONSTRICTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; PHOSPHORYLATION; SMOOTH MUSCLE CELL; VASCULAR RESISTANCE; WISTAR KYOTO RAT;

ACETYLCYSTEINE; ANIMALS; CELLS, CULTURED; CHOLESTEROL ESTER TRANSFER PROTEINS; FREE RADICAL SCAVENGERS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; OXIDATION-REDUCTION; PHOSPHORYLATION; PROTEIN PHOSPHATASE 1; PYRAZOLES; PYRIDINES; RATS; RATS, INBRED WKY; STAT3 TRANSCRIPTION FACTOR; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 84963827948     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.230748     Document Type: Article

References (28)

1. Barter PJ, Brewer HB, Jr, Chapman MJ, Hennekens CH, Rader DJ, and Tall AR (2003) Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23:160-167.
2. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, and Waters DD, et al.; ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122.
3. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, and Grobbee DE, et al.; RADIANCE 2 Investigators (2007) Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370:153-160.
4. Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, and Mitchel Y, et al.; DEFINE Investigators (2015) Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol 9:65-71.
5. Chang RL, Xie L, Xie L, Bourne PE, and Palsson BO (2010) Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLOS Comput Biol 6:e1000938.
6. Clerc RG, Stauffer A, Weibel F, Hainaut E, Perez A, Hoflack JC, Bénardeau A, Pflieger P, Garriz JM, and Funder JW, et al. (2010) Mechanisms underlying offtarget effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels. J Hypertens 28:1676-1686.
7. Dalvie D, Chen W, Zhang C, Vaz AD, Smolarek TA, Cox LM, Lin J, and Obach RS (2008) Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos 36:2185-2198.
8. Derks M, Abt M, Phelan M, Turnbull L, Meneses-Lorente G, Bech N, White AM, and Parr G (2010) Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 50:1188-1201.
9. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, and McPherson HE, et al. (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154:1465-1473.
10. Gotto AM, Jr, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, and Shah S, et al. DEFINE Investigators (2014) Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther 19:543-549.
11. Hilgers RH and Webb RC (2005) Molecular aspects of arterial smooth muscle contraction: focus on Rho. Exp Biol Med (Maywood) 230:829-835.
12. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, Yuan H, Perry DA, and Keiser J (2009) Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 150:2211-2219.
13. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, and Tall AR (1990) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234-1238.
14. Johnson AW, Kinzenbaw DA, Modrick ML, and Faraci FM (2013) Small-molecule inhibitors of signal transducer and activator of transcription 3 protect against angiotensin II-induced vascular dysfunction and hypertension. Hypertension 61:437-442.
15. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, and Shear CL, et al.; RADIANCE 1 Investigators (2007) Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356:1620-1630.
16. Kirchmer MN, Franco A, Albasanz-Puig A, Murray J, Yagi M, Gao L, Dong ZM, and Wijelath ES (2014) Modulation of vascular smooth muscle cell phenotype by STAT-1 and STAT-3. Atherosclerosis 234:169-175.
17. Krishna R, Garg A, Panebianco D, Cote J, Bergman AJ, Van Hoydonck P, Laethem T, Van Dyck K, Chen J, and Chavez-Eng C, et al. (2009) Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 68:535-545.
18. Montezano AC and Touyz RM (2014) Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research. Antioxid Redox Signal 20:164-182.
19. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, and Tuzcu EM; ILLUSTRATE Investigators (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356:1304-1316.
20. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, and Shinkai H (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:203-207.
21. Reho JJ, Zheng X, and Fisher SA (2014) Smooth muscle contractile diversity in the control of regional circulations. Am J Physiol Heart Circ Physiol 306:H163-H172.
22. Rios FJ, Neves KB, Nguyen Dinh Cat A, Even S, Palacios R, Montezano AC, and Touyz RM (2015) Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes. J Pharmacol Exp Ther 353:27-34.
23. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, and Leiter LA, et al.; dal-OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089-2099.
24. Simic B, Hermann M, Shaw SG, Bigler L, Stalder U, Dörries C, Besler C, Lüscher TF, and Ruschitzka F (2012) Torcetrapib impairs endothelial function in hypertension. Eur Heart J 33:1615-1624.
25. Tall AR (1986) Plasma lipid transfer proteins. J Lipid Res 27:361-367.
26. Teramoto T, Takeuchi M, Morisaki Y, Ruotolo G, and Krueger KA (2014) Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia. Am J Cardiol 113:2021-2029.
27. Touyz RM, Tolloczko B, and Schiffrin EL (1994) Mesenteric vascular smooth muscle cells from spontaneously hypertensive rats display increased calcium responses to angiotensin II but not to endothelin-1. J Hypertens 12:663-673.
28. Webb RC (2003) Smooth muscle contraction and relaxation. Adv Physiol Educ 27:201-206.